HOME >> BIOLOGY >> NEWS
Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting

Snowmass, Co. (September 9, 2004) Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

Below are reports on three presentations.

  • Anti-adhesion therapy in the treatment of IBD Julian Panes and Josep M. Pique of the Gastroenterology Department of the Hospital Clinic Barcelona, Spain, note that the localization for leukocytes to inflammatory areas has key implications in the pathogenesis, diagnosis and treatment of IBD. A major effort has been directed toward identifying and characterizing the adhesion glycoproteins that enable leukocytes to bind to vascular endothelial cells. Drugs that specifically target adhesion molecules involved in leukocyte recruitment are effective in treating intestinal inflammation.

    They said that experimental models have shown that blockade of VLA-4, VCAM-1 and P-selectin afford significant amelioration of intestinal inflammation. In experimental models, response to adhesion molecule blockage varies according to the type of inflammatory intestinal condition. In humans VLA-4 immunoneutralization has been effective in inducing remission in Crohn's Disease, but no data is available for ulcerative colitis.

    The researchers call for experimental and clinical controlled trials comparing the effectiveness of different strategies of CAM blockade, and suggest that this therapeutic approach be compared with current therapies.

  • Platelet recruitment in intestinal inflammation modulated by ICAM-1, P-selectin, PSGL-1

    Researchers from LSU and the University of Muenster studied the mechanisms responsible for platelet-WBC and platelet-endothelial cell (EC) interactions that occur in exper
    '"/>



  • Contact: Mayer Resnick
    mresnick@the-aps.org
    301-634-7209
    American Physiological Society
    9-Sep-2004


    Page: 1 2 3

    Related biology news :

    1. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
    2. Novel approaches to current cellular therapies continue progress toward disease prevention
    3. Novel therapies show promise against myeloid leukemia
    4. Novel sensors help clear the air
    5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
    6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
    7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
    8. Novel bacterium detoxifies chlorinated pollutants
    9. Novel flu vaccine shows promise in mice
    10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
    11. Novel method identifies hidden genes

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:8/15/2019)... ... August 15, 2019 , ... Deep Science Ventures ... Food and Agriculture practice, a new unit dedicated to building 100 companies over the ... raw materials and supply chains. , Deep Science Ventures was founded to create ...
    (Date:8/14/2019)... ... ... Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, BioTel Research ... EDT to learn about two common imaging methods in NAFLD/NASH to aid with early ... diffuse liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided ...
    (Date:8/9/2019)... ... , ... With a demand in healthcare to lower unneeded emergency room visits ... centers (UCC) in the coming years, according to a new report on the industry ... Centers , is a detailed look at the current state of these healthcare outlets, ...
    Breaking Biology News(10 mins):
    (Date:6/11/2019)... , ... June 10, 2019 , ... ... and technology in an upcoming episode, scheduled to broadcast 4Q/2019. Check your local ... Group) and will educate viewers about how its technology facilitates laboratories to improve ...
    (Date:6/11/2019)... Md. and ROANOKE, Va. (PRWEB) , ... June ... ... care optimized for microlearning engagement, and Carilion Clinic, a national leader in opioid ... the latest in virtual care. , Mytonomy recently deployed its virtual ...
    (Date:6/11/2019)... N.C. (PRWEB) , ... June 11, 2019 , ... ... extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to incorporate ... cloning ability. In a test on mice, MSC-EVs also increased the cells’ ability ...
    (Date:5/31/2019)... ... , ... For many years, the primary forms of cancer treatment have been ... in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR T) ... known as “CARs”. The CAR enables the final product to produce chemicals in the ...
    Breaking Biology Technology:
    Cached News: